OncoMatch/Clinical Trials/NCT05002816
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Is NCT05002816 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Elotuzumab and Belantamab mafodotin for multiple myeloma.
Treatment: Elotuzumab · Belantamab mafodotin — The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunomodulatory drug
Prior line of therapy must include iMID
Must have received: proteasome inhibitor
Prior line of therapy must include ... proteasome inhibitor
Must have received: anti-CD38 monoclonal antibody
Prior line of therapy must include ... anti-CD38 monoclonal antibody
Cannot have received: monoclonal antibody
Exception: prior elotuzumab is allowed
Participant must not have received prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs
Cannot have received: systemic anti-myeloma therapy
Exception: systemic steroids are allowed
Participant must not have used an investigational drug or approved systemic anti-myeloma therapy (systemic steroids are allowed) within 14 days preceding the first dose of study drug
Cannot have received: plasmapheresis
Participant must not have had plasmapheresis within 7 days prior to first dose of study treatment
Cannot have received: major surgery
Participant must not have had major surgery ≤ 4 weeks prior to initiating study treatment
Lab requirements
Blood counts
ANC ≥0.5X 10^9/L; Hemoglobin ≥8.0 g/dL; Platelets ≥50X 10^9/L
Kidney function
eGRF ≥30 mL/min/ 1.73 m2; Spot urine (albumin/creatinine ratios) <500 mg/g (56 mg/mmol) OR Urine dipstick Negative/trace (if ≥1+ only eligible if confirmed <500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void))
Liver function
Total bilirubin ≤1.5X ULN (Isolated bilirubin ≥1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%); ALT ≤2.5 X ULN
Participant must have adequate organ function, defined as: ANC ≥0.5X 10 9/L; Hemoglobin ≥8.0 g/dL; Platelets ≥50X 10 9/L; Total bilirubin ≤1.5X ULN (Isolated bilirubin ≥1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%); ALT ≤2.5 X ULN; eGRF ≥30 mL/min/ 1.73 m2; Spot urine (albumin/creatinine ratios) <500 mg/g (56 mg/mmol) OR Urine dipstick Negative/trace (if ≥1+ only eligible if confirmed <500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void))
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Yale New Haven Hospital · New Haven, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify